68Ga-pentixafor PET/CT in the localization diagnosis of primary aldosteronism concurrent subclinical cushing's syndrsome: two case reports

Xin Wei,Feifei Wu,Haoyu Dong,Ying Jing,Ying Song,Hua Pang,Jing Chen,Zhipeng Du,Wenwen He,Linqiang Ma,Yue Wang,Jinbo Hu,Qifu Li,Shumin Yang,Mei Mei,Suxin Luo,Kangla Liao,Yao Zhang,Yunfeng He,Yihong He,Ming Xiao,Bin Peng,on behalf of the Chongqing Primary Aldosteronism Study (CONPASS) Group
DOI: https://doi.org/10.1007/s12020-024-03865-6
2024-06-26
Endocrine
Abstract:Adrenal venous sampling (AVS) is recommended for subtyping primary aldosteronism (PA). However, in cases of PA, concurrent subclinical Cushing's syndrome (SCS) has the potential to confound AVS results. Pentixafor, a CXC chemokine receptor type 4–specific ligand, has been reported as a promising marker to evaluate functional nature of adrenal adenomas. This study aims to investigate the clinical value of Gallium-68 Pentixafor Positron Emission Tomography–Computed Tomography ( 68 Ga-Pentixafor PET/CT) in the localization diagnosis of patients with PA plus SCS.
endocrinology & metabolism
What problem does this paper attempt to address?